((S)-5-{5-[(5-Cyano-pyridine-2-carbonyl)-amino]-2-fluoro-phenyl}-5-difluoromethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-yl)-carbamic acid tert-butyl ester → Ethanol heptane

((S)-5-{5-[(5-Cyano-pyridine-2-carbonyl)-amino]-2-fluoro-phenyl}-5-difluoromethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-yl)-carbamic acid tert-butyl ester (67.7 mg, 0.134 mmol) was dissolved in 0.75 mL dichloromethane and 0.25 mL trifluoroacetic acid. The solution was stirred at for 45 minutes and then evaporated at room temperature. The residue was dissolved in EtOAc and extracted with saturated aqueous NaHCO3 solution. The layers were washed with brine and EtOAc. The combined organic layers were dried over Na2SO4 and evaporated. The crude product was dissolved in THF, 0.2 mL HCl solution 1 mol/L in diethyl ether was added and the mixture was evaporated. The residue was crystallized from ethanol and TBME to give 48 mg of the title compound as white crystals.

1. customevaporated at room temperature
2. dissolutionThe residue was dissolved in EtOAc
3. extractionextracted with saturated aqueous NaHCO3 solution
4. washThe layers were washed with brine and EtOAc
5. dry with materialThe combined organic layers were dried over Na2SO4
6. customevaporated
7. dissolutionThe crude product was dissolved in THF
8. addition0.2 mL HCl solution 1 mol/L in diethyl ether was added
9. customthe mixture was evaporated
10. customThe residue was crystallized from ethanol and TBME

ORD-Eintrag

ord-586a144163db44618412439093ae75c4

Quelldatensatz

uspto-grants-2012_06

DOI

10.6084/m9.figshare.5104873.v1

Patentnummer

US08207164B2